| Literature DB >> 27591000 |
S Harrow1, G G Hanna2, C Faivre-Finn3, F McDonald4, A J Chalmers5.
Abstract
Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop. CrownEntities:
Keywords: DNA damage repair; NSCLC; immunotherapy; radiotherapy; umbrella study
Mesh：
Substances：
Year: 2016 PMID： 27591000 DOI： 10.1016/j.clon.2016.08.004
Source DB: PubMed Journal: Clin Oncol (R Coll Radiol) ISSN： 0936-6555 Impact factor: 4.126